<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05794737</url>
  </required_header>
  <id_info>
    <org_study_id>Soh-Med-23-03-08MS</org_study_id>
    <nct_id>NCT05794737</nct_id>
  </id_info>
  <brief_title>Immunohistochemical Expression of Inhibin Beta A (INHBA) in Colorectal Carcinoma</brief_title>
  <official_title>Immunohistochemical Expression of Inhibin Beta A (INHBA) in Colorectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A retrospective observational study to evaluate immunohistochemical expression of Inhibin&#xD;
      Beta A (INHBA) in 60 cases of Colorectal Carcinoma, and compare levels of its expression to&#xD;
      different clinicopathological criteria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colorectal Carcinoma is an aggressive malignant epithelial tumor with an observable high&#xD;
      incidence. Tumor invasion and metastasis to distant sites are two important issues which&#xD;
      determine patient's outcome, so detecting novel biological markers that are involved in tumor&#xD;
      proliferation and invasion with subsequent targeting by future medical drugs will positively&#xD;
      improve patient's prognosis.&#xD;
&#xD;
      Inhibin Beta A (INHBA) is a glycoprotein molecule that has a role in tumor cells&#xD;
      proliferation and invasion in different human malignancies. The aim of this study is to&#xD;
      detect expression of INHBA in 60 archived formalin-fixed Paraffin-embedded tissue blocks of&#xD;
      patients suffered from Colorectal Carcinoma, and to correlate different levels of its&#xD;
      expression to some studied clinical and pathological criteria (Age, Sex, Tumor size,&#xD;
      location, depth of tumor invasion, status of regional lymph nodes, vascular and perineural&#xD;
      invasion).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of INHBA in Colorectal Carcinoma.</measure>
    <time_frame>6 months</time_frame>
    <description>Detection of expression of INHBA in Colorectal Carcinoma cells by immunohistochemical approach, using anti-human INHBA monoclonal antibody.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between INHBA expression in Colorectal Carcinoma and clinicopathological parameters.</measure>
    <time_frame>6 months</time_frame>
    <description>Correlation between different levels of INHBA expression in Colorectal Carcinoma cells and some clinical and pathological parameters as age, sex, tumor phenotype and nodal status.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Participants</arm_group_label>
    <description>60 archived Formalin-fixed Paraffin-embedded tissue blocks of Colorectal Carcinoma will be obtained and sectioned. From each block; Two tissue sections will be prepared, one tissue section will be stained by Hematoxylin and Eosin to detect tumor phenotype and depth of invasion. Other tissue section will be immunohistochemically stained by Anti-Human INHBA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immunohistochemical staining</intervention_name>
    <description>Staining of Colorectal Carcinoma tissue sections by monoclonal antibodies against human Inhibin Beta A by immunohistochemical procedures.</description>
    <arm_group_label>Participants</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      60 formalin fixed, Paraffin embedded Colorectal Cancer tissue blocks.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Archived Formalin-fixed, Paraffin-embedded tissue blocks belonged to patients suffered from&#xD;
        colonic and/or rectal cancers. Patients were admitted to sohag university hospital and&#xD;
        underwent colectomy and their colonic specimens were sent to Pathology Laboratory of the&#xD;
        same hospital to ascertain diagnosis and tumor phenotype, from period Janurary 2021 to&#xD;
        December 2022.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Specimens from patients with Colorectal Carcinoma. Tissue blocks with sufficient material.&#xD;
        Specimens with sufficient clinical data.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Tissue blocks with insufficient, destroyed or necrotic material. Specimens with&#xD;
        insufficient clinical data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mera A Fayez, Doctor</last_name>
    <phone>01224890136</phone>
    <email>meraatef@med.sohag.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sohag University hospitals</name>
      <address>
        <city>Sohag</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdy M Amin, Professor</last_name>
    </contact>
    <contact_backup>
      <last_name>Mera A Fayez, Doctor</last_name>
      <phone>01224890136</phone>
      <email>meraatef@med.sohag.edu.eg</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 20, 2023</study_first_submitted>
  <study_first_submitted_qc>March 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 20, 2023</last_update_submitted>
  <last_update_submitted_qc>March 20, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Mera Atef Fayez</investigator_full_name>
    <investigator_title>Teaching Assistant of Pathology</investigator_title>
  </responsible_party>
  <keyword>Inhibin Beta A</keyword>
  <keyword>Colorectal Carcinoma</keyword>
  <keyword>Immunohistochemistry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

